MedTrace Logo

Safety and Effectiveness of NeuroStar® Transcranial Magnetic Stimulation (TMS) Therapy in Depressed Adolescents

NCT02586688 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 112

Last updated 2025-06-12

Study results available
· View outcomes & findings →

Summary

To evaluate the safety and efficacy of daily, active Neurostar® TMS (when compared with sham treatment) in adolescents meeting criteria for Major Depressive Disorder (MDD).

Conditions

Interventions

DEVICE

Active NeuroStar® Transcranial Magnetic Stimulation (TMS)

Compare active NeuroStar® coil with sham NeuroStar® coil.

DEVICE

Sham NeuroStar® Transcranial Magnetic Stimulation (TMS)

Compare active NeuroStar® coil with sham NeuroStar® coil.

Sponsors & Collaborators

  • Neuronetics

    lead OTHER

Principal Investigators

  • Paul Croarkin, MD · Mayo Clinic

  • Karen Heart · Neuronetics

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
12 Years
Max Age
21 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-10-31
Primary Completion
2018-01-31
Completion
2018-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02586688 on ClinicalTrials.gov